Treatment of Acute Gout Flare

Initial Management Approach

The European League Against Rheumatism recommends treating acute gout flares as early as possible, ideally within 12-24 hours of symptom onset for maximum efficacy 1, 2
Patients should be educated to self-medicate at the first warning symptoms using the "pill in the pocket" approach 1, 3
The choice of medication should be based on the presence of contraindications, patient's previous experience with treatments, time since symptom onset, and number and type of joints involved 1, 2, 4

Colchicine is most effective when given within 12 hours of symptom onset 1, 3
The recommended dosing is 1.2 mg at the first sign of flare followed by 0.6 mg one hour later, for a maximum dose of 1.8 mg over a one-hour period 5, 2
Low-dose regimen is as effective as higher doses with fewer gastrointestinal side effects 5, 2
Contraindications for colchicine include severe renal impairment and concomitant use of strong P-glycoprotein and/or CYP3A4 inhibitors 1

NSAIDs should be used at full FDA-approved anti-inflammatory/analgesic doses 2, 6
Options include naproxen, indomethacin, or other NSAIDs 1, 2
Consider adding a proton pump inhibitor in patients with gastrointestinal risk factors 1, 4
Contraindications for NSAIDs include renal disease, heart failure, and cirrhosis 5, 3, 7

Oral prednisone or prednisolone can be used at a dose of 30-35 mg/day for 3-5 days 1, 5
Intra-articular corticosteroid injection can be used for monoarticular gout 1, 7
Corticosteroids are generally safer in patients with renal impairment or cardiovascular disease 5, 7
Potential adverse effects include dysphoria, mood disorders, elevated blood glucose, and fluid retention 5, 2

For mild to moderate pain with limited joint involvement, monotherapy with any of the first-line agents is appropriate 2, 6
For severe pain or polyarticular involvement, combination therapy may be more effective 1, 6

In patients with renal impairment, corticosteroids are generally safer than NSAIDs or colchicine 5, 7
In patients with cardiovascular disease, oral corticosteroids are preferred over NSAIDs 5, 7
In elderly patients, dose selection should be cautious and corticosteroids may be preferred due to lower risk of serious adverse effects compared to NSAIDs 5, 7

Established urate-lowering therapy should be continued without interruption during an acute attack 2
Ice application to affected joints can provide additional pain relief 7
For patients not responding adequately to initial monotherapy, adding a second appropriate agent is acceptable 1, 6
Avoid combining NSAIDs and systemic corticosteroids due to potential synergistic gastrointestinal toxicity 6

The European League Against Rheumatism recommends avoiding colchicine in patients with severe renal impairment (GFR <30 mL/min) 8
The European League Against Rheumatism contraindicates colchicine in patients receiving strong P-glycoprotein and/or CYP3A4 inhibitors such as cyclosporin or clarithromycin 9

For patients with normal renal function, the European League Against Rheumatism suggests that any of the first-line agents (colchicine, NSAIDs, or corticosteroids) can be used based on patient preference and previous experience 9

The European League Against Rheumatism recommends considering IL-1 blockers (canakinumab) for patients with contraindications to colchicine, NSAIDs, and corticosteroids, but notes that current infection is a contraindication to IL-1 blockers 8

The European League Against Rheumatism recommends prophylaxis during the first 6 months of urate-lowering therapy, with colchicine 0.5-1 mg/day as the recommended prophylactic treatment, and low-dose NSAIDs as an alternative if colchicine is not tolerated or contraindicated 9

The American College of Rheumatology recommends initiating treatment with one of three equally effective first-line agents: colchicine, NSAIDs, or oral corticosteroids, with the single most critical factor for treatment success being early initiation within 12-24 hours of symptom onset 10
The European League Against Rheumatism suggests that the choice of first-line agent should be based on patient preference and previous experience, with all three options being equally effective 11, 10

The American College of Rheumatology conditionally recommends initiating urate-lowering therapy during a flare, with concomitant anti-inflammatory prophylaxis 11
The American College of Rheumatology strongly recommends concomitant anti-inflammatory prophylaxis for 3-6 months when starting urate-lowering therapy, with low-dose colchicine 0.5-0.6 mg once or twice daily as the first-line prophylaxis 11, 10